|
1
|
Rugge M, Genta RM, Di Mario F, El-Omar EM,
El-Serag HB, Fassan M, Hunt RH, Kuipers EJ, Malfertheiner P, Sugano
K and Graham DY: Gastric cancer as preventable disease. Clin
Gastroenterol Hepatol. 15:1833–1843. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kosaka T, Endo M, Toya Y, Abiko Y, Kudara
N, Inomata M, Chiba T, Takikawa Y, Suzuki K and Sugai T: Long-term
outcomes of endoscopic submucosal dissection for early gastric
cancer: A single-center retrospective study. Dig Endosc.
26:183–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ilson DH: Advances in the treatment of
gastric cancer. Curr Opin Gastroenterol. 34:465–468. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao T, Xie A, Liu X, Zhan H, Zeng J, Dai M
and Zhang B: Toosendanin induces the apoptosis of human Ewing's
sarcoma cells via the mitochondrial apoptotic pathway. Mol Med Rep.
20:135–140. 2019.PubMed/NCBI
|
|
5
|
Zhou Q, Wu X, Wen C, Wang H, Wang H, Liu H
and Peng J: Toosendanin induces caspase-dependent apoptosis through
the p38 MAPK pathway in human gastric cancer cells. Biochem Biophys
Res Commun. 505:261–266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang G, Huang Y, Zhang R, Hou L, Liu H,
Chen X, Zhu J and Zhang J: Toosendanin suppresses oncogenic
phenotypes of human gastric carcinoma SGC-7901 cells partly via
miR-200a-mediated downregulation of β-catenin pathway. Int J Oncol.
51:1563–1573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams BD, Parsons C, Walker L, Zhang WC
and Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest.
127:761–771. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu HH, Lin WC and Tsai KW: Advances in
molecular biomarkers for gastric cancer: miRNAs as emerging novel
cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Wang Q, Liu H, Hu B, Zhou W and
Cheng Y: MicroRNA expression and its implication for the diagnosis
and therapeutic strategies of gastric cancer. Cancer Lett.
297:137–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Han R, Chen X, Li Y, Zhang S, Li R and Lu
L: MicroRNA-34a suppresses aggressiveness of hepatocellular
carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Manag
Res. 11:2963–2976. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang T, Zeng H, Chen W, Zheng R, Zhang Y,
Li Z, Qi J, Wang M, Chen T, Lou J, et al: Helicobacter pylori
infection, H19 and LINC00152 expression in serum and risk of
gastric cancer in a Chinese population. Cancer Epidemiol.
44:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Melton C, Li Y, Shenoy A, Zhang X,
Subramanyam D and Blelloch R: miR-294/miR-302 promotes
proliferation, suppresses G1-S restriction point, and inhibits ESC
differentiation through separable mechanisms. Cell Rep. 4:99–109.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu XH, Lu KH, Wang KM, Sun M, Zhang EB,
Yang JS, Yin DD, Liu ZL, Zhou J, Liu ZJ, et al: MicroRNA-196a
promotes non-small cell lung cancer cell proliferation and invasion
through targeting HOXA5. BMC Cancer. 12:3482012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding F, Lai J, Gao Y, Wang G, Shang J,
Zhang D and Zheng S: NEAT1/miR-23a-3p/KLF3: A novel regulatory axis
in melanoma cancer progression. Cancer Cell Int. 19:2172019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu P, Wang C, Ma C, Wu Q, Zhang W and Lao
G: MicroRNA-23a regulates epithelial-to-mesenchymal transition in
endometrial endometrioid adenocarcinoma by targeting SMAD3. Cancer
Cell Int. 16:672016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He Y, Meng C, Shao Z, Wang H and Yang S:
MiR-23a functions as a tumor suppressor in osteosarcoma. Cell
Physiol Biochem. 34:1485–1496. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen B, Zhu A, Tian L, Xin Y, Liu X, Peng
Y, Zhang J, Miao Y and Wei J: miR23a suppresses pancreatic cancer
cell progression by inhibiting PLK1 expression. Mol Med Rep.
18:105–112. 2018.PubMed/NCBI
|
|
18
|
Rigotto C, Sincero TC, Simões CM and
Barardi CR: Detection of adenoviruses in shellfish by means of
conventional-PCR, nested-PCR, and integrated cell culture PCR
(ICC/PCR). Water Res. 39:297–304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen C, Ridzon DA, Broomer KJ, Zhou ZH,
Lee DH, Nguyen JT, Barbisin N, Xu LN, Mahuvakar VR, Andersen MR, et
al: Real-time quantification of microRNAs by stem-loop RT-PCR.
Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sui CG, Meng FD, Li Y and Jiang YH:
miR-148b reverses cisplatin-resistance in non-small cell cancer
cells via negatively regulating DNA (cytosine-5)-methyltransferase
1(DNMT1) expression. J Transl Med. 13:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schenk RL, Strasser A and Dewson G: BCL-2:
Long and winding path from discovery to therapeutic target. Biochem
Biophys Res Commun. 482:459–469. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cory S and Adams JM: The Bcl2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J,
Wang H, Zuo D, Wang G, Hua Y and Cai Z: Toosendanin demonstrates
promising antitumor efficacy in osteosarcoma by targeting STAT3.
Oncogene. 36:6627–6639. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang G, Feng C, Chu S, Zhang R, Lu Y, Zhu
J and Zhang J: Toosendanin inhibits growth and induces apoptosis in
colorectal cancer cells through suppression of
AKT/GSK-3beta/beta-catenin pathway. Int J Oncol. 47:1767–1774.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu XL, Wang H, Zhang L, Wang YL, Wang J,
Wang P, He X and He YJ: Anticancer effects of crude extract from
Melia toosendan Sieb. et Zucc on hepatocellular carcinoma in vitro
and in vivo. Chin J Integr Med. 22:362–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang S, Cao L, Wang ZR, Li Z and Ma J:
Anti-cancer effect of toosendanin and its underlying mechanisms. J
Asian Nat Prod Res. 21:270–283. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao S, Wen Z, Liu S, Liu Y, Li X, Ge Y
and Li S: MicroRNA-148a inhibits the proliferation and promotes the
paclitaxel-induced apoptosis of ovarian cancer cells by targeting
PDIA3. Mol Med Rep. 12:3923–3929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hua K, Chen YT, Chen CF, Tang YS, Huang
TT, Lin YC, Yeh TS, Huang KH, Lee HC, Hsu MT, et al:
MicroRNA-23a/27a/24-2 cluster promotes gastric cancer cell
proliferation synergistically. Oncol Lett. 16:2319–2325.
2018.PubMed/NCBI
|
|
31
|
Wang G, Li B, Fu Y, He M, Wang J, Shen P
and Bai L: miR-23a suppresses proliferation of osteosarcoma cells
by targeting SATB1. Tumour Biol. 36:4715–4721. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng Y, Deng Z, Hao H, Wu X, Gao H, Tang S
and Tang H: MicroRNA-23a promotes colorectal cancer cell survival
by targeting PDK4. Exp Cell Res. 373:171–179. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weyhenmeyer B, Murphy AC, Prehn JH and
Murphy BM: Targeting the anti-apoptotic Bcl-2 family members for
the treatment of cancer. Exp Oncol. 34:192–199. 2012.PubMed/NCBI
|
|
34
|
Liao ZB, Tan XL, Dong KS, Zhang HW, Chen
XP, Chu L and Zhang BX: miRNA-448 inhibits cell growth by targeting
BCL-2 in hepatocellular carcinoma. Dig Liver Dis. 51:703–711. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen J, Zhou J, Chen X, Yang B, Wang D,
Yang P, He X and Li H: miRNA-449a is downregulated in osteosarcoma
and promotes cell apoptosis by targeting BCL2. Tumour Biol.
36:8221–8229. 2015. View Article : Google Scholar : PubMed/NCBI
|
